PPARγ as a therapeutic target for tumor angiogenesis and metastasis

Panigraphy, Danik, Huang, Sui, Kieran, Mark W., Kaipainen, Arja·2005·Cancer Biology & Therapy
DOI 10.4161/cbt.4.7.2014

Cited by (137)

Items 101–137 of 137

  1. PPAR-γ inhibitors as novel tubulin-targeting agents
    Katherine L. Schaefer · 2007 · Expert Opinion on Investigational Drugs
  2. Design, synthesis, docking, ADMET and anticancer evaluations of N -alkyl substituted iodoquinazoline derivatives as dual VEGFR-2 and EGFR inhibitors
    Marwa Alsulaimany, Khaled El‐Adl, Ahmed K. B. Aljohani et al. · 2023 · RSC Advances
  3. PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes
    Ancha V. Baranova · 2008 · PPAR Research
  4. TNF-alpha and melphalan modulate a specific group of early expressed genes in a murine melanoma model
    Vladmir Cláudio Cordeiro de Lima, Alex Fiorini de Carvalho, Mariana Morato-Marques et al. · 2013 · Cytokine
  5. PPARγ: The Portrait of a Target Ally to Cancer Chemopreventive Agents
    Ioannis Sainis, Katerina Vareli, Vasilios Karavasilis, Evangelos C. Briasoulis · 2008 · PPAR Research
  6. Head and neck cancers, the neglected malignancies: present and future treatment strategies
    Pushkar Kulkarni, Uday Saxena · 2014 · Expert Opinion on Therapeutic Targets
  7. The anti‐tumor effects of cosmosiin through regulating AhR / CYP1A1 ‐ PPARγ in breast cancer
    Dan Wang, Jing Zhang, Houqing Yin, Ribai Yan, Zequn Wang, Jinhai Deng, Gang Li, Yan Pan · 2024 · The FASEB Journal
  8. Analysis of SIKVAV’s receptor affinity, pharmacokinetics, and pharmacological characteristics: a matrikine with potent biological function
    Lívia Alves Filgueiras, Francisco das Chagas Pereira de Andrade, Samuel Iwao Maia Horita, Shubhangi D. Shirsat, Varenyam Achal, Mahendra Rai, Andrea Henriques‐Pons, Anderson Nogueira Mendes · 2024 · Journal of Biomolecular Structure and Dynamics
  9. Diabetes and cancer: Could vitamin D provide the link?
    Shahzaib Ahmad, Tahseen Ahmad Chowdhury, Barbara Joan Boucher · 2012 · Journal of Diabetes and its Complications
  10. C-reactive Protein in Patients with Metastatic Clear Cell Renal Carcinoma: An Important Biomarker for Tumor-associated Inflammation
    Albrecht Reichle, Jochen Grassinger, K. Bross · 2006 · Biomarker Insights
  11. Differential Effects of Cancer-Associated Mutations Enriched in Helix H3 of PPARγ
    Dong Man Jang, Jun Young Jang, Hyun‐Jung Kim · 2020 · Cancers
  12. PPARγ is a tumor suppressor in basal bladder tumors offering new potential therapeutic opportunities
    Laure Coutos-Thévenot, Syrine Beji, Hélène Neyret‐Kahn, Quentin Pippo, Jacqueline Fontugne, Judit Ősz, Clémentine Krucker, Clarice S. Groeneveld, Florent Dufour, Aurélie Kamoun et al. · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
  13. Crossing Boundaries: A Review of the Diverse Functions of Heterocyclic Compounds in the Management of Cancer and Infectious Diseases
    Pranay Wal, Ankita Wal, Talha Jawaid · 2025 · Current Drug Targets
  14. Combination of paclitaxel with rosiglitazone induces synergistic cytotoxic effects in ovarian cancer cells
    Binita Patel, Shanaya Patel, Foram M. Modi, Aditi Patel, Brijesh Gelat, Vivek Tanavde, Abhay Raghukant Vasavada, Kaid Johar · 2024 · Scientific Reports
  15. Rational design, docking, syntheses, ADMET and cytotoxicity assessments of iodoquinazoline derivatives as inhibitors of EGFRT790M and VEGFR-2
    Ahmed K. B. Aljohani, Marwa Alsulaimany, Omar M. Alatawi et al. · 2025 · Journal of Molecular Structure
  16. Molecular Insight and Preclinical Perspective of Thymoquinone as Chemopreventive Agent and Therapeutic Adjunct in Cancer
    Sanjeev Banerjee, Mansi A. Parasramka, Fazlul H. Sarkar · 2012 · Springer eBooks
  17. C-Reactive Protein As a Secretome-Derived Biomarker for Predicting Response to Biomodulatory Therapy in Metastatic Renal Clear Cell Carcinoma
    Bernhard Walter, Irmela Schrettenbrunner, Martin Vogelhuber et al. · 2010 · Springer eBooks
  18. New quinazoline-N-4-fluorophenyl derivatives as potential anticancer agents: Discovery of a promising dual EGFR/VEGFR-2 inhibitor
    Mohammed H. Geesi · 2024 · Journal of King Saud University - Science
  19. Integrated network pharmacology and experimental verification to explore the potential mechanism of San Ying decoction for treating triple-negative breast cancer
    Xiaojuan Yang, Feifei Li, Youyang Shi et al. · 2024 · Acta Biochimica et Biophysica Sinica
  20. Neuroendocrine tumors and diabetes mellitus: which treatment and which effect
    Rossella Mazzilli, Virginia Zamponi, Camilla Mancini, Beatrice Giorgini, Bianca Golisano, Nevena Mikovic, Giulia Pecora, Flaminia Russo, Maurizio Martiradonna, Piero Paravani et al. · 2025 · Endocrine
  21. 6 Iodo-delta lactone inhibits angiogenesis in human HT29 colon adenocarcinoma xenograft.
    Romina Oglio, Buschittari Federico, Leonardo A. Salvarredi · 2022 · Prostaglandins Leukotrienes and Essential Fatty Acids
  22. Angiogenesis, Arteriogenesis, and Mitochondrial Dysfunction
    Michael Sean McMurtry · 2013 · Springer eBooks
  23. MicroRNA-130b Promotes Tumor Development and Is Associated with Poor Prognosis in
    Tommaso Colangelo, Alessandra Fucci, Carolina Votino et al. · 2013
  24. Angiogenesis-Based Therapies for Eye Diseases
    Rajkumar V. Patil, Chee Wai Wong, Fabio Michelet, Kelvin Yi Chong Teo, Daniel Shu Wei Ting, Andrew S. H. Tsai, Chui Ming Gemmy Cheung, Tien Yin Wong · 2017 · Springer eBooks
  25. A putative role for platelet-derived PPARγ in vascular homeostasis demonstrated by anti-PPARγ induction of bleeding, thrombocytopenia and compensatory megakaryocytopoiesis
    Patricia J. Simpson‐Haidaris, Kathryn E. Seweryniak, Sherry L. Spinelli · 2010 · Journal of Biotechnology
  26. Exploration of cytotoxicity of iodoquinazoline derivatives as inhibitors of both VEGFR‐2 and EGFRT790M: Molecular docking, ADMET, design, and syntheses
    Marwa Alsulaimany, Sanadelaslam S. A. El‐Hddad, Zuhir S. M. Akrim et al. · 2024 · Archiv der Pharmazie
  27. Functional Genomic Analysis of Breast Cancer Cell Tumorigenicity Using a Novel Gene Silencing Resource
    Douglas S. Conklin · 2005
  28. Peroxisome proliferator-activated receptor gamma activator inhibits cell growth of MDA-MB-231 breast cancer cells through induction of apoptosis
    Eun Jeong Jo, Hyun Jo Youn, Sung Hoo Jung · 2006 · Journal of Breast Cancer
  29. The PPARγ Agonist Rosiglitazone Inhibits Glioma Cell Proliferation and Migrationin vitroand Glioma Tumor Growthin vivo
    Chang Hwa Choi, Chae Hwa Kwon, Yong Keun Kim · 2009 · Experimental Neurobiology
  30. KUOPION YLIOPISTON JULKAISUJA C. LUONNONTIETEET JA YMPÄRISTÖTIETEET 207 KUOPIO UNIVERSITY PUBLICATIONS C. NATURAL AND ENVIRONMENTAL SCIENCES 207
    Merja Matilainen · 2007
  31. ReviewArticle PPARs Mediate Lipid Signaling in Inflammation and Cancer
    Liliane Michalik, Walter Wahli · 2008
  32. ReviewArticle PPARγ and Agonists against Cancer: Rational Design of Complementation Treatments
    Dorina Veliceasa, Frank T. Schulze-Hoepfner, Olga V. Volpert · 2008
  33. ReviewArticle PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes
    Ancha V. Baranova · 2008
  34. Establishment of fluorescence-based affinity assay systems for the investigation of nuclear receptor dimerization and ligand modulated coregulator recruitment
    Whitney Tandiwe Kala Kilu · 2021
  35. Endolysosomal effectors and their relevance for antiviral activity against the Hepatitis E virus
    Mirco Glitscher · 2021
  36. Elucidation of putative key genes involved in the regulation of triple negative breast cancer development and progression
    Alok Kumar, Gauri Shankar Upadhyay, Mohammad Kashif, Md. Zubbair Malik, Naidu Subbarao, Maitreyi S. Rajala · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  37. Design, synthesis, molecular docking, ADMET and anticancer evaluation of novel pyridine/thiazole hybrids as dual VEGFR-2 and EGFR kinase inhibitors
    Naglaa M. Ahmed, Rizk Elsayed Khidre, Mohamed R. Khidre · 2026 · Bioorganic Chemistry